Bristol Myers Squibb to Present Phase 2 Pumitamig Lung Cancer Data at ESMO 2026
Bitget2026/10/19 11:04- Bristol Myers Squibb will present cancer trial data at ESMO 2026 in Madrid, October 23-27, including two late-breaking Phase 3 iza-bren studies.
- Iza-bren presentations will cover previously treated breast cancer and EGFR-mutant lung cancer; Biokin sponsored both Phase 3 trials.
- Pumitamig, jointly developed with BioNTech, will feature in late-breaking global Phase 2 findings evaluating treatment for metastatic lung cancer.
- Final overall survival results from CheckMate 8HW will compare Opdivo with Yervoy against Opdivo alone or chemotherapy in metastatic colorectal cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan: Stabilization of bond yields may end valuation compression, combined with accelerating earnings, stock market expected to rise through the end of the year
JPMorgan stated that stabilized yields may help extend the stock market rally through the end of the year.
Wells Fargo: This earnings season marks "one of the weakest starts for EPS in history," with most companies underperforming expectations
Wells Fargo stated that the start of this US earnings season has been unfavorable. In its report, the bank wrote that only about a week into the third-quarter earnings season, the earnings per share of companies that have reported results are already 0.3% lower than analysts’ general expectations.
Metals Focus analysts remain bullish on gold: consolidating rather than turning bearish, with support near $4,000
Analysts from Metals Focus stated that the gold market is currently in a consolidation phase, rather than entering a bear market.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
